Pfizer | Cytosar – U (Medication)
Cytosar – U: Indications
Cytosar – U/cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytosar – U is indicated in the prophylaxis and treatment of meningeal leukemia….
Cytosar – U: Side Effects
Nausea, vomiting, loss of appetite, diarrhea, headache, dizziness, and pain/swelling/redness at the injection site may occur. Nausea and vomiting can be severe. In some cases, drug therapy may be needed to prevent or relieve nausea and vomiting. Not eating before your treatment may help relieve vomiting. Changes in diet such as eating several small meals or limiting activity may help lessen some of these effects. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.
Temporary hair loss may occur. Normal hair growth should return after treatment has ended. Tell your doctor right away if you have any serious side effects, including: fever with body aches, muscle/bone pain, chest pain, eye redness/itching/pain, painful/difficult swallowing, anal sores, change in the amount of urine, painful/difficult urination, joint/side/back pain, pain/redness/swelling of the arms/legs/feet, numbness or tingling of hands/feet, freckling, big toe pain, trouble breathing, black/bloody stools, blood in the urine, vomit that looks like coffee grounds, vision problems (including blindness), mental/mood changes (e.g., confusion), unexplained drowsiness, unconsciousness, enlarged abdomen, trouble walking, muscle weakness, loss of coordination, inability to move (paralysis), seizures.
This medication can lower the body’s ability to fight an infection. Notify your doctor promptly if you develop any signs of an infection such as fever, chills, unusual cough, or persistent sore throat.
Seek immediate medical attention if you experience any symptoms of a serious allergic reaction may include: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing….
Cytosar – U: Precaution
Patients receiving Cytosar – U must be monitored closely. Frequent platelet and leukocyte counts and bone marrow examinations are mandatory. Counts of formed elements in the peripheral blood may continue to fall after the drug is stopped and reach lowest values after drug-free intervals of 12 to 24 days.
When large intravenous doses are given quickly, patients are frequently nauseated and may vomit for several hours postinjection. This problem tends to be less severe when the drug is infused.
The human liver apparently detoxifies a substantial fraction of an administered dose. In particular, patients with renal or hepatic function impairment may have a higher likelihood of CNS toxicity after high-dose Cytosar – U treatment. Use the drug with caution and possibly at reduced dose in patients whose liver or kidney function is poor. Periodic checks of bone marrow, liver and kidney functions should be performed in patients receiving Cytosar – U.
Like other cytotoxic drugs, Cytosar – U may induce hyperuricemia secondary to rapid lysis of neoplastic cells. The clinician should monitor the patient’s blood uric acid level and be prepared to use such supportive and pharmacologic measures as might be necessary to control this problem.
Acute pancreatitis has been reported to occur in patients being treated with Cytosar – U who have had prior treatment with L-asparaginase….